The world market for insulin was valued at US$3.5 billion in 2001.  Europe accounted for 40% of the market and the US for 38%. Human insulin is an epidemiology driven market and epidemiologically speaking diabetes is on the rise. 

Due to increased knowledge regarding improved therapy with insulin, physicians are steadily switching NIDDM to human insulin, thus increasing the total market.  Doctor's awareness of the disease and its means of diagnosis are improving which is increasing the patient pool.  

Although the insulin market has been stable for a long time due to sheer size and fortification of the two leading producers and the high barriers to entry, this is about to change soon with the introduction of new delivery systems and new players on the world stage. Of particular interest is the eminent launch of inhalation insulin products by Pfizer, Aventis and Novo Nordisk

Human Insulin, State-of-the-Science & Strategic Opportunities is a strategic business report that assesses both the technology status and the competitive landscape of the world insulin market. The report examines both the US and the European markets in detail, profiles leading products and companies and offers revenue forecasts to the year 2007.  The report assesses the market attractiveness and potential and evaluates the impact of new product launch on the market.

Report Code: 0212AS1B

Date Published: November 2002

Number of Pages: 28 

Publisher: AS Insights Opportunity and Valuation Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Bioportfolio_AS_Insights_Opportunity_and_Valuation_Reports__10.html#a515